ArticleJournal of neuro-oncology2015

Bevacizumab decreases vestibular schwannomas growth rate in children and teenagers with neurofibromatosis type 2.

Audrey Hochart et al.PubMed ↗Publisher ↗

No numbers read from the abstract.